NSE - Delayed Quote INR

AstraZeneca Pharma India Limited (ASTRAZEN.NS)

8,119.50
+149.00
+(1.87%)
At close: 3:29:59 PM GMT+5:30
Currency in INR All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
16,190,100
12,955,300
10,029,700
8,056,000
8,085,600
Cost of Revenue
9,956,500
6,732,600
4,252,600
3,574,600
3,305,400
Gross Profit
6,233,600
6,222,700
5,777,100
4,481,400
4,780,200
Operating Expense
4,305,200
4,508,400
4,288,200
3,784,900
3,617,600
Operating Income
1,928,400
1,714,300
1,488,900
696,500
1,162,600
Net Non Operating Interest Income Expense
318,600
313,700
224,900
105,300
93,700
Pretax Income
1,322,500
2,195,400
1,341,000
830,400
1,270,900
Tax Provision
352,800
580,300
348,100
214,400
337,900
Net Income Common Stockholders
969,700
1,615,100
992,900
616,000
933,000
Diluted NI Available to Com Stockholders
969,700
1,615,100
992,900
616,000
933,000
Basic EPS
38.78
64.60
39.70
24.60
37.30
Diluted EPS
38.78
64.60
39.70
24.60
37.30
Basic Average Shares
25,004.13
25,000
25,000
25,000
25,000
Diluted Average Shares
25,004.13
25,000
25,000
25,000
25,000
Rent Expense Supplemental
--
4,600
0
400
3,900
Total Expenses
14,261,700
11,241,000
8,540,800
7,359,500
6,923,000
Net Income from Continuing & Discontinued Operation
969,700
1,615,100
992,900
616,000
933,000
Normalized Income
1,646,620.26
1,503,130.33
1,272,555.73
597,232.18
919,859.15
Interest Income
--
325,700
231,200
114,800
104,600
Interest Expense
7,100
12,000
6,300
9,500
10,900
Net Interest Income
318,600
313,700
224,900
105,300
93,700
EBIT
1,329,600
2,207,400
1,347,300
839,900
1,281,800
EBITDA
1,590,200
2,356,800
1,509,900
1,009,400
1,479,300
Reconciled Cost of Revenue
9,956,500
6,732,600
4,252,600
3,574,600
3,305,400
Reconciled Depreciation
260,600
149,400
162,600
169,500
197,500
Net Income from Continuing Operation Net Minority Interest
969,700
1,615,100
992,900
616,000
933,000
Total Unusual Items Excluding Goodwill
-923,200
152,200
-377,700
25,300
17,900
Total Unusual Items
-923,200
152,200
-377,700
25,300
17,900
Normalized EBITDA
2,513,400
2,204,600
1,887,600
984,100
1,461,400
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-246,279.74
40,230.33
-98,044.27
6,532.18
4,759.15
3/31/2021 - 7/1/2002

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ABBOTINDIA.NS Abbott India Limited
30,065.00
-0.33%
 
MOREPENLAB.BO Morepen Laboratories Limited
60.38
+7.38%
 
ERIS.NS Eris Lifesciences Limited
1,404.90
-3.51%
 
BAJAJHCARE.NS Bajaj HealthCare Limited
552.10
+6.44%
 
SUVENPHAR.NS Cohance Lifesciences Limited
1,063.30
-1.35%
 
WOCKPHARMA.BO Wockhardt Limited
1,270.85
+3.49%
 
MANKIND.NS Mankind Pharma Limited
2,500.00
+3.81%
 
GLAND.NS Gland Pharma Limited
1,430.10
+0.29%
 
SIGACHI.NS Sigachi Industries Limited
42.58
+3.40%
 
SUVEN.NS Suven Life Sciences Limited
153.07
+7.46%